{"denoms":[{"counts":[{"groupId":"BG000","value":"116"}],"units":"Participants"}],"groups":[{"description":"Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.","id":"BG000","title":"Blinatumomab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"16.4","value":"44.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"}]}],"title":"≥ 18 and <35 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"41"}]}],"title":"≥ 35 and < 55 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"24"}]}],"title":"≥ 55 and < 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}],"title":"≥ 65 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"48"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"68"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"102"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Mixed"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"Unknown"}],"description":"Race was not permitted to be collected in France.","paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Positive"},{"categories":[{"measurements":[{"groupId":"BG000","value":"111"}]}],"title":"Negative"}],"paramType":"NUMBER","title":"Philadelphia Chromosome Disease Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"88"}],"title":"No"},{"measurements":[{"groupId":"BG000","value":"23"}],"title":"Unknown"}]}],"description":"t(4;11)(q21;q23) translocation, resulting in the fusion of the mixed lineage leukemia (MLL) gene on chromosome 11 and the AF4 gene on chromosome 4","paramType":"COUNT_OF_PARTICIPANTS","title":"Confirmed t(4;11) Translocation / MLL-AF4+ ALL","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"≥ 10^-1 and < 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"45"}]}],"title":"≥ 10^-2 and < 10^-1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"52"}]}],"title":"≥ 10^-3 and < 10^-2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"< 10^-3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Below Lower Limit of Quantification"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Unknown"}],"description":"Measured by polymerase chain reaction (PCR) performed on bone marrow and assessed by the central laboratory; Lower limit of quantification was at least 10\\^-4 leukemic cells.","paramType":"NUMBER","title":"MRD Level at Baseline by Central Laboratory","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"78"}]}],"title":"≤ 30,000/mL"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}],"title":"> 30,000/mL"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"Unknown"}],"paramType":"NUMBER","title":"White Blood Cells at First Diagnosis","unitOfMeasure":"participants"}],"populationDescription":"Full analysis set (all participants who received any infusion of blinatumomab)"}